100 filings
8-K
COLL
Collegium Pharmaceutical, Inc.
4 Sep 24
Collegium Completes Acquisition of Ironshore Therapeutics
8:03am
8-K
COLL
Collegium Pharmaceutical, Inc.
8 Aug 24
Collegium Reports Second Quarter 2024 Financial Results
4:01pm
8-K
COLL
Collegium Pharmaceutical, Inc.
29 Jul 24
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
6:02am
8-K
COLL
Collegium Pharmaceutical, Inc.
13 Jun 24
Other Events
8:05am
8-K
COLL
Collegium Pharmaceutical, Inc.
24 May 24
Departure of Directors or Certain Officers
4:05pm
8-K
k8uyv196hd
20 May 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
xjfohe fw1dlpxlogw0f
13 May 24
Other Events
8:05am
8-K
fkgqxk5a8cmt
10 May 24
Departure of Directors or Certain Officers
8:02am
8-K
3onu r89mg2
9 May 24
Collegium Reports First Quarter 2024 Financial Results
4:04pm
8-K
9ffkoe6x0p79 00
29 Apr 24
Entry into a Material Definitive Agreement
8:05am
8-K
219qdxiknhlpkuztvffz
11 Apr 24
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
8:00am
8-K
stj5pt 4tf
22 Feb 24
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
4:01pm
8-K
ddjaw
3 Jan 24
Regulation FD Disclosure
8:03am
8-K
h44x 79hjq4v
9 Nov 23
Other Events
8:05am
8-K
1fwez9t
7 Nov 23
Collegium Reports Third Quarter 2023 Financial Results
4:01pm
8-K
sb58qrb0g9z5a 2su2
24 Aug 23
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
8:05am
8-K
42smzy wox
7 Aug 23
Other Events
7:40am
8-K
1t2xo851
3 Aug 23
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
4:03pm
8-K
k83z8
19 May 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
kza8zmh q4uvpskprrr
4 May 23
Collegium Reports First Quarter 2023 Financial Results
4:01pm